Pharmacokinetics and safety of ceftolozane/tazobactam in haemodialysis patients with severe renal impairment or end-stage renal disease

Trial Profile

Pharmacokinetics and safety of ceftolozane/tazobactam in haemodialysis patients with severe renal impairment or end-stage renal disease

Completed
Phase of Trial: Phase I

Latest Information Update: 20 Feb 2014

At a glance

  • Drugs Ceftolozane/tazobactam (Primary)
  • Indications Gram-negative infections; Intra-abdominal infections; Nosocomial pneumonia; Urinary tract infections
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Cubist Pharmaceuticals
  • Most Recent Events

    • 20 Feb 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top